KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF.
about
Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategiesDiabetes and retinal vascular dysfunction.Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical PracticeDesigner Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Animal Models of Diabetic Retinopathy.New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein OcclusionTherapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.Kaempferol targets estrogen-related receptor α and suppresses the angiogenesis of human retinal endothelial cells under high glucose conditions.Slit2/Robo1 signaling is involved in angiogenesis of glomerular endothelial cells exposed to a diabetic-like environment.Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.Models of retinal diseases and their applicability in drug discovery.Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.Placental growth factor promotes epithelial-mesenchymal transition-like changes in ARPE-19 cells under hypoxia.A novel mechanism of action for salidroside to alleviate diabetic albuminuria: effects on albumin transcytosis across glomerular endothelial cells.
P2860
Q33912480-516221AE-D57E-4713-B6DA-4C07691E72B7Q35017752-CB4F296C-E2DB-401F-AED4-68E1389D7709Q36173627-EF27CC20-4F84-4B6E-AD4F-9D0587661C44Q36176814-51131AC8-0A92-4774-871B-757D6DECD49AQ36200924-1B8CFBD7-229D-4F17-8B6E-5ACFFFD556BDQ38401907-F4CD250B-A0DA-4AA7-B2E8-8B80E534549BQ38848800-E76EC073-230D-4045-9DBA-4263FB109FD8Q41843866-53F02C97-F70F-4983-BFC7-E6261051861DQ47093960-2AFDB366-AD86-4A44-A2B5-489D8E18CBFFQ47233538-99025F06-90E4-4E1B-B0B1-B8AF66BC8F61Q47704189-0C3A6A0D-0D01-4B9A-9CB8-5270B8DC5076Q47905437-300888DB-BA74-4F4E-A2E8-964136923844Q49574913-060C93A1-770E-4586-B5E2-7EB8F6F2F5D2Q53373714-FD4F4A6C-2725-4ADF-865E-68D3FFB780DBQ54957577-B4B585A2-7ACF-45F0-AE90-9C0649812D5CQ55034880-061C6426-D35A-46F7-82F6-813A002FB72E
P2860
KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@en
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@nl
type
label
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@en
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@nl
prefLabel
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@en
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@nl
P2093
P2860
P356
P1476
KH902 suppresses high glucose- ...... lls by blocking VEGF and PIGF.
@en
P2093
P2860
P304
P356
10.1111/DOM.12008
P577
2012-09-30T00:00:00Z